Hologic’s (HOLX) “Outperform” Rating Reiterated at William Blair

Hologic (NASDAQ:HOLX)‘s stock had its “outperform” rating reissued by William Blair in a note issued to investors on Monday,RTT News reports.

A number of other brokerages have also commented on HOLX. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Monday. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Jefferies Financial Group assumed coverage on Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price objective on the stock. UBS Group upped their target price on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, Wolfe Research assumed coverage on Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating for the company. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Hologic presently has an average rating of “Moderate Buy” and a consensus price target of $88.92.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $70.20 on Monday. The company has a market cap of $15.93 billion, a price-to-earnings ratio of 21.08, a PEG ratio of 2.32 and a beta of 0.97. The business has a 50 day moving average price of $75.61 and a 200 day moving average price of $78.53. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic has a twelve month low of $69.46 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the company posted $0.89 earnings per share. Research analysts predict that Hologic will post 4.28 earnings per share for the current year.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.75% of the company’s stock.

Institutional Investors Weigh In On Hologic

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp grew its holdings in shares of Hologic by 0.8% during the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after purchasing an additional 81,057 shares during the last quarter. FMR LLC grew its holdings in Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after acquiring an additional 2,174,093 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Hologic by 0.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock valued at $208,051,000 after acquiring an additional 18,774 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Hologic by 8.6% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock worth $200,952,000 after acquiring an additional 195,285 shares during the last quarter. Finally, Black Creek Investment Management Inc. lifted its position in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after purchasing an additional 885,524 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.